Despite significant progress in the development of improved body weight- and blood glucose-lowering drugs such as the stable glucagon-like peptide 1 (GLP-1) analogue semaglutide, bariatric surgeries remain the gold-standard treatment option for severe obesity [5]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.